Novavax Statistics
Total Valuation
Novavax has a market cap or net worth of $1.29 billion. The enterprise value is $643.79 million.
Important Dates
The last earnings date was Tuesday, November 12, 2024, before market open.
Earnings Date | Nov 12, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Novavax has 160.18 million shares outstanding. The number of shares has increased by 59.45% in one year.
Current Share Class | 160.18M |
Shares Outstanding | 160.18M |
Shares Change (YoY) | +59.45% |
Shares Change (QoQ) | -3.50% |
Owned by Insiders (%) | 0.30% |
Owned by Institutions (%) | 53.13% |
Float | 143.39M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 1.30 |
Forward PS | 2.91 |
PB Ratio | n/a |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 0.73 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.93
Current Ratio | 0.93 |
Quick Ratio | 0.89 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -17.46 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -10.76% |
Return on Capital (ROIC) | n/a |
Revenue Per Employee | $573,683 |
Profits Per Employee | -$184,613 |
Employee Count | 1,543 |
Asset Turnover | 0.53 |
Inventory Turnover | 19.68 |
Taxes
In the past 12 months, Novavax has paid $5.12 million in taxes.
Income Tax | 5.12M |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +42.37% in the last 52 weeks. The beta is 2.09, so Novavax's price volatility has been higher than the market average.
Beta (5Y) | 2.09 |
52-Week Price Change | +42.37% |
50-Day Moving Average | 10.91 |
200-Day Moving Average | 10.11 |
Relative Strength Index (RSI) | 36.54 |
Average Volume (20 Days) | 5,793,053 |
Short Selling Information
The latest short interest is 39.98 million, so 24.96% of the outstanding shares have been sold short.
Short Interest | 39.98M |
Short Previous Month | 35.72M |
Short % of Shares Out | 24.96% |
Short % of Float | 27.88% |
Short Ratio (days to cover) | 5.90 |
Income Statement
In the last 12 months, Novavax had revenue of $885.19 million and -$284.86 million in losses. Loss per share was -$1.99.
Revenue | 885.19M |
Gross Profit | 115.46M |
Operating Income | -290.02M |
Pretax Income | -288.88M |
Net Income | -284.86M |
EBITDA | -243.25M |
EBIT | -290.02M |
Loss Per Share | -$1.99 |
Full Income Statement Balance Sheet
The company has $909.53 million in cash and $262.23 million in debt, giving a net cash position of $647.31 million or $4.04 per share.
Cash & Cash Equivalents | 909.53M |
Total Debt | 262.23M |
Net Cash | 647.31M |
Net Cash Per Share | $4.04 |
Equity (Book Value) | -526.44M |
Book Value Per Share | -3.29 |
Working Capital | -77.32M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$90.88 million and capital expenditures -$19.96 million, giving a free cash flow of -$110.85 million.
Operating Cash Flow | -90.88M |
Capital Expenditures | -19.96M |
Free Cash Flow | -110.85M |
FCF Per Share | -$0.69 |
Full Cash Flow Statement Margins
Gross margin is 13.04%, with operating and profit margins of -32.76% and -32.18%.
Gross Margin | 13.04% |
Operating Margin | -32.76% |
Pretax Margin | -31.60% |
Profit Margin | -32.18% |
EBITDA Margin | -27.48% |
EBIT Margin | -32.76% |
FCF Margin | -2.39% |
Dividends & Yields
Novavax does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -59.45% |
Shareholder Yield | -59.45% |
Earnings Yield | -22.06% |
FCF Yield | -8.59% |
Analyst Forecast
The average price target for Novavax is $17.83, which is 121.77% higher than the current price. The consensus rating is "Buy".
Price Target | $17.83 |
Price Target Difference | 121.77% |
Analyst Consensus | Buy |
Analyst Count | 6 |
Revenue Growth Forecast (5Y) | -2.34% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
The last stock split was on May 10, 2019. It was a reverse split with a ratio of 0.05:1.
Last Split Date | May 10, 2019 |
Split Type | Reverse |
Split Ratio | 0.05:1 |
Scores
Novavax has an Altman Z-Score of -3.81 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -3.81 |
Piotroski F-Score | 3 |